Express News | Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc

Breakings19:45

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT NewswiresDec 14 02:53

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

BenzingaDec 14 01:15

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

BenzingaDec 13 20:50

Merck & Co. Gets Key European Backing for Welireg in Two Uses

WSJDec 13 20:30

Express News | Merck: Final Decision Is Expected in Q1 of 2025

BreakingsDec 13 20:05